# Hong Jian

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hong-jian/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,073 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 22 |
| i10-index | 31 |
| Last Known Institution | Shanghai Jiao Tong University |
| OpenAlex ID | https://openalex.org/A5102832210 |
| ORCID iD | 0000-0002-7749-7313 |
| Works | 61 |

## Researcher papers

- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)
- [Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/sintilimab-plus-bevacizumab-biosimilar-ibi305-and-chemotherapy-for-patients-with/)
- [Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-patients-with-egfr-mutated-non-squamous-non/)
- [Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial](https://scholariq.org/papers/safety-efficacy-and-pharmacokinetics-of-almonertinib-hs-10296-in-pretreated/)
- [Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial](https://scholariq.org/papers/traditional-chinese-medicine-treatment-as-maintenance-therapy-in-advanced-non/)
- [Variability of <i>EGFR</i> exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors](https://scholariq.org/papers/variability-of-i-egfr-i-exon-20-insertions-in-24-468-chinese-lung-cancer/)
- [SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer](https://scholariq.org/papers/sema4b-inhibits-mmp9-to-prevent-metastasis-of-non-small-cell-lung-cancer/)
- [Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients](https://scholariq.org/papers/objective-and-subjective-financial-burden-and-its-associations-with-health/)
- [Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study](https://scholariq.org/papers/befotertinib-d-0316-versus-icotinib-as-first-line-therapy-for-patients-with-egfr/)
- [SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo](https://scholariq.org/papers/sema4b-inhibits-growth-of-non-small-cell-lung-cancer-in-vitro-and-in-vivo/)
- [Clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC.](https://scholariq.org/papers/clinical-and-genetic-characteristics-of-egfr-mutant-lung-adenocarcinoma/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Shanghai Jiao Tong University](https://scholariq.org/institutions/shanghai-jiao-tong-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.